Oncology Associates of Oregon

Eugene, Oregon 97401

8 studies enrolling now · 21 studies all time

What they study most

ARID1A Gene Mutation, Advanced Solid Tumor, Breast Neoplasms, Cancer, Carcinoma, Non-Small Cell Lung, Endometrial Adenocarcinoma, Endometrial Cancer, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Higher-risk Myelodysplastic Syndromes, Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)

Studies at this site

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) — Recruiting now
• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation — Recruiting now
• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL — Recruiting now
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma — Recruiting now
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer — Recruiting now
• Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma — Recruiting now
• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) — Recruiting now
• A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer — Recruiting now
• A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes — Recruiting now
• Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer — Recruiting now
• A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer — Stopped early
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] — Completed
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• Development and Validation of Harbinger Health Test for Early Cancer Detection — Completed
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer — Completed
• A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes — Stopped early
• Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC — Completed
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients — Completed